103733-40-0

Basic information

• Product Name: Moexipril tert-Butyl Ester Maleic Acid Salt
• Synonyms: (3S)-2-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]aMino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-diMethoxy-3-isoquinolinecarboxylic Acid 1,1-DiMethylethyl Ester;Moexipril Related CoMpound C;(3S)-2-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid 1,1-dimethylethyl ester (2Z)-2-butenedioate (1:1);Moexipril tert-butyl ester maleate;Moexipril tert-Butyl Ester Maleic Acid Salt;(2Z)-2-Butenedioate
• CAS NO: 103733-40-0
• Molecular Formula: C₃₁H₄₂N₂O₇
• Molecular Weight: 670.74654
• Product Categories: Aromatics;Chiral Reagents;Impurities;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 103733-40-0.mol
• Article Data: 2

Chemical Properties

• Melting Point: 148-150°C
• Appearance: /
• Storage Temp.: -20?C Freezer
• Solubility: DMSO, Methanol
• CAS DataBase Reference: Moexipril tert-Butyl Ester Maleic Acid Salt(CAS DataBase Reference)
• NIST Chemistry Reference: Moexipril tert-Butyl Ester Maleic Acid Salt(103733-40-0)
• EPA Substance Registry System: Moexipril tert-Butyl Ester Maleic Acid Salt(103733-40-0)

Safety Data

• Hazardous Substances Data: 103733-40-0(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

An impurity of Moexipril (M485350).

Upstream product

• 84793-24-8 N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanine N-carboxyanhydride 
• 103733-66-0 tert-butyl (S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
• 82717-96-2 [1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanine 
• 32161-30-1 (S)-3,4-dimethoxyphenylalanine 
• 76824-86-7 (S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
• 80828-26-8 N-[1-(S)-(ethoxycarbonyl)-3-phenylpropyl]-L-alanine hydrochloride 

Relevant articles and documents

Continuous Flow Synthesis of ACE Inhibitors From N-Substituted l-Alanine Derivatives

A strategy for the continuous flow synthesis of angiotensin converting enzyme (ACE) inhibitors is described. An optimization effort guided by in situ IR analysis resulted in a general amide coupling approach facilitated by N-carboxyanhydride (NCA) activation that was further characterized by reaction kinetics analysis in batch. The three-step continuous process was demonstrated by synthesizing 8 different ACE inhibitors in up to 88 % yield with throughputs in the range of ≈0.5 g h?1, all while avoiding both isolation of reactive intermediates and process intensive reaction conditions. The process was further developed by preparing enalapril, a World Health Organization (WHO) essential medicine, in an industrially relevant flow platform that scaled throughput to ≈1 g h?1.